| Study characteristics |
| Methods |
C: unknown
Blinding not stated
Ex during trial: unknown
Losses to FU: unknown |
| Participants |
Poland
120 participants
Mean age: 57 years
65% male
100% CT before entry
Enrolled less than 48 hours after ischaemic stroke |
| Interventions |
Rx: fraxiparin (LMWH)
0.6 mL 12‐hourly for 1 week, then 0.3 mL 12‐hourly for 1 week
Control: placebo
Duration: 14 days |
| Outcomes |
Death
Functional outcome
Intracerebral haemorrhage (symptomatic CT)
Symptomatic DVT and PE during treatment period |
| Notes |
Ex: > 65 years, comatose, severe comorbidity, uncontrolled hypertension
FU: 3 months |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
No methods reported for random generation |
| Allocation concealment (selection bias) |
Unclear risk |
Allocation concealment not described |
| Blinding (performance bias and detection bias)
All outcomes |
High risk |
Blinded design not reported |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
Blinded design not reported |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
Blinded design not reported |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No loss to follow‐up reported during treatment period |
| Selective reporting (reporting bias) |
Unclear risk |
Abstract without full details of reporting outcomes |
